BCM
FSTX

BlueCrest Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

BlueCrest Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,069
Closed -$189K – 1929
2018
Q1 		$189K Buy
+3,069
New +$162K 0.01% 1287

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlueCrest Capital Management's FSTX Position: Q2 2018 in Review

BlueCrest Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2018, closing a stake of 3,069 shares — an estimated $189K sold.

BlueCrest Capital Management first reported a position in FSTX in Q1 2018 and held it in 1 quarter. The position peaked at $189K in Q1 2018. 52 funds tracked by Wall St. Rank hold FSTX as of Q2 2018.

  • BlueCrest Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 3,069 F-star Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $189K.
  • BlueCrest Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $189K in Q1 2018.
  • 52 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.